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Given the escalating worldwide socioeconomic burden of 
Alzheimer’s disease (AD), there is a strong impetus for 
better therapeutics. Currently, there are approved symp-
tomatic drugs but very few disease-modifying agents 
capable of slowing down or reversing disease progression.
As the Alzheimer’s Drug Discovery Foundation 
(ADDF) executive director Howard Fillit (ADDF, New 
York, NY, USA) pointed out in his opening remarks, 
major issues include the diﬃ     culty in drugging central 
nervous system targets and the predictability of AD 
animal models. Preclinical trials have so far demonstrated 
hundreds of ‘cures’, yet the track record for translating 
these treatments to the human disease is lackluster, as 
evidenced by the recent spate of high-proﬁ  le failures.
Alzheimer’s disease biomarkers
An overarching theme of the conference was disease 
prevention and early treatment before AD manifests 
signiﬁ  cant cognitive decline, when it is probably too late 
to reverse the substantial neural pathology. To create 
preventative treatments, however, we ﬁ  rst need accurate 
and reliable biomarker diagnostics to identify prodromal 
AD (mild cognitive impairment and even earlier).
As Holly Soares (Bristol-Myers Squibb, New York, NY, 
USA) pointed out, biomarkers are also critical for patient 
selection and monitoring treatment eﬃ   cacy  in  AD 
clinical trials. Th  e Alzheimer’s Disease Neuroimaging 
Initiate has proposed cerebrospinal ﬂ  uid amyloid-β (Aβ) 
levels and amyloid positron emission tomography 
imaging as good biomarkers for early detection. Dawn 
Matthews (Abiant, Inc., Grayslake, IL, USA) expanded on 
the use of neuroimaging techniques as diagnostic tools. 
For example, ﬂ   uorodeoxyglucose positron emission 
tomography imaging can sensi  tively detect changes in 
various brain regions, even in pre-mild cognitive 
impairment, and follows cognitive decline in AD. Quality 
control in data acquisition, processing, and analysis is 
critical, however, for the successful use of neuroimaging 
methods as diagnostics.
In addition to neuroimaging and cerebrospinal ﬂ  uid 
analyses, there is a need for simpler, less invasive tests. 
Rima Kaddurah-Daouk (Duke University Medical Center, 
Durham, NC, USA) discussed metabolomics as a 
minimally invasive tech  nique that allows the examination 
of global biochemical signatures. In AD, several pathways 
are disturbed, including those for norephinephrine and 
ceramides, indicating that metabolites from these path-
ways could be useful in diagnostic analyses. Stephen 
Johnston (Arizona State University Foundation, Tempe, 
AZ, USA) presented another new non-invasive diagnostic 
technique – immunosignatures – which is based on 
screening the antibody population of an individual on 
random peptide sequence arrays. Dr Johnston demon-
strated in preliminary tests the ability to detect distinct 
immunosignatures in AD samples, which are not due to 
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Alzheimer’s Disease Neuroimaging Initiate samples will 
determine whether this approach holds promise for 
early-AD detection.
In addition to AD, there are several related dementias 
that overlap heavily, including dementia with Lewy 
bodies and frontotemporal dementia (FTD), which also 
require better biomarker tests to aid diagnosis. Lawrence 
Honig (Columbia University, New York, NY, USA) 
proposed that a combination of biomarkers can diﬀ  er-
entiate dementia with Lewy bodies, including the use of 
glucocerebrosidase as a genetic marker, neuroimaging, 
and cerebrospinal ﬂ  uid analyses. For example, although 
cerebrospinal ﬂ  uid Aβ levels are similar to those found in 
AD, tau and phospho-tau levels are relatively normal. 
Linda Kwong (University of Pennsylvania School of 
Medicine, Phila  delphia, PA, USA) discussed biomarker 
diagnostics for FTD and presented her preliminary data 
demonstrating that ELISA screening of plasma TDP-43 
levels may diﬀ  erentiate between FTD-tau and FTD-TDP.
Targeting amyloid-β linked pathologies
A well-publicized drug discovery approach in AD is the 
manipulation of Aβ metabolism by the modulation or 
inhibition of the β-secretase and γ-secretase enzymes 
that process amyloid precursor protein (APP). Tae-Wan 
Kim (Columbia University, New York, NY, USA) 
presented his work on indirect, small-molecule BACE1 
modulators that can reduce secreted Aβ levels in 
neuronal cultures and in transgenic APP mice. Dr Kim is 
currently working on identifying the cellular targets and 
mechanisms of action.
Another approach to lower Aβ in the brain is through 
the inhibition of RAGE, which transports Aβ across the 
blood–brain barrier. Rashid Deane (University of Rochester, 
Rochester, NY, USA) is testing some lead compounds 
that can block Aβ–RAGE interactions at multiple points 
across cell types. When tested in Tg2575 transgenic mice, 
these compounds were able to reduce brain Aβ levels, to 
improve blood ﬂ  ow, and to ameliorate cognitive decline.
Targeting other pathways disrupted by Aβ could also 
yield eﬀ   ective therapeutics. For example, there is a 
signiﬁ  cant link between AD and cardiovascular dys  func-
tion. Sidney Strickland (Rockefeller University, Rocke-
feller, NY, USA) discussed his studies showing that Aβ 
can bind ﬁ  brinogen and alter blood clot structure and 
dissolution. Reducing ﬁ   brinogen pharmacolo  gically or 
genetically improved learning and memory in AD 
transgenic mice, indicating that this protein could be a 
target for AD drug discovery. Looking at another aspect 
of this process, Chris Schaﬀ  er (Cornell University, Ithaca, 
NY, USA) described a method to induce speciﬁ  c 
microvascular clots using a laser scalpel to make single 
micron-size cuts in blood-vessel endo  thelial cells. He 
showed that these microvascular clots induce new Aβ 
deposits locally and increased inﬂ  am  mation.
Since apolipoprotein E (ApoE) is currently the most 
signiﬁ  cant genetic risk factor for late-onset AD, we need to 
better understand its underlying mechanisms to develop 
new treatments and aid interpretation of clinical trials that 
demonstrate diﬀ  erential eﬃ   cacy depending on the ApoE 
genotype. Cheryl Wellington (University of British 
Columbia Hospital, Vancouver, BC, Canada) observed that 
highly lipidated ApoE is protective in AD, possibly due to 
the facilitation of Aβ degradation. Dr Wellington is 
currently screening chemical libraries for compounds that 
can enhance ApoE lipidation and secretion, with retinoic 
acid and progestin as preliminary hits.
Eric Schon (Columbia University, New York, NY, USA) 
found that presenilins – components of the γ-secretase 
complex that play important roles in Aβ metabolism, 
among other functions – are enriched in mitochondria-
associated membranes. Dr Schon hypothesizes that many 
aspects of AD pathology arise from mitochondria-
associated membrane dysfunction. Cells from presenilin 
knockout mice as well as from sporadic AD patients have 
enhanced sensitivity to cinnamycin, which could be used 
as a possible diagnostic tool for screening mitochondria-
associated membrane-targeted compounds.
Neuroprotection and cognitive enhancement:
Th  e primary goal for AD therapeutics is to prevent 
neuronal damage and improve cognitive function, a goal 
that is being pursued via many diﬀ  erent  approaches. 
Scott Noggle (Th   e New York Stem Cell Foundation, New 
York, NY, USA) discussed stem cell technology as a way 
to specify cell types involved in neurodegeneration. In 
particular, induced pluripotent stem cell lines derived 
from AD patients could be especially valuable for both 
basic research and drug discovery screening programs; 
several familial AD lines are currently in development.
Various compounds that can improve cognition were 
presented in the rest of this session. Roberta Brinton 
(University of Southern California, Los Angeles, CA, 
USA) introduced allopregnanolone, a progesterone 
metabolite that is able to improve memory and 
neurogenic defects in 3xTg mice as well as in normally 
aged wild-type mice. Th  ese bene  ﬁ  cial  eﬀ   ects are only 
observed in transgenic mice younger than 1 year old, 
however, with the biggest improvements in young pre-
plaque 3-month-old mice, indicating that allopregnano-
lone should be used as an early preventative treatment. 
Ottavio Arancio (Columbia University, New York, NY, 
USA) discussed cAMP responsive element-binding 
protein, which is a key transcription factor involved in 
synaptic plasticity that has been shown to be impaired by 
Aβ. Dr Arancio’s laboratory recently demonstrated that 
sildena ﬁ   l, an approved phosphodiesterase-5 inhibitor, 
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phosphory  lation, synaptic plasticity, and learning and 
memory in APP/PS1 transgenic mice. After demon-
strating that phosphodiesterase-5 is highly expressed in 
the human brain, Dr Arancio is working on optimizing 
lead phospho  diesterase-5 inhibitors.
Klotho, a secreted hormone that acts on multiple path-
ways in aging and metabolism, was presented as another 
possible drug target by Carmela Abraham (Boston 
University School of Medicine, Boston, MA, USA). Dr 
Abraham dis  covered that while Klotho knockout mice 
have an accelerated aging phenotype that includes 
cognitive impairment, Klotho-overexpressing mice have 
increased life spans and enhanced resistance to oxidative 
stress. A high-throughput screen of chemical libraries 
identiﬁ  ed several lead compounds that increase Klotho 
expression and will be tested for protective eﬀ  ects against 
Aβ-induced pathology.
High brain levels of striatal enriched tyrosine phos  pha-
tase (STEP) are found in several neurological diseases 
including AD. Paul Lombroso (Yale University, New 
Haven, CT, USA) found that increased STEP levels can 
impair synaptic plasticity and memory due to the dephos-
phorylation and subsequent internalization of glutamate 
receptors. A high-throughput screen identiﬁ  ed  STEP 
inhibitor lead compounds, which rescued behavioral 
tasks in transgenic mouse models a few hours after 
treatment, compared with the weeks of treatment neces-
sary with memantine.
Another mechanism for cognitive dysfunction in AD 
could be hippocampal hyperexcitability, which is found 
in mild cognitive impairment patients and suggests that 
an attenuation of neuronal excitability could be a 
therapeutic strategy. As detailed by Michela Gallagher 
(Johns Hopkins University, Baltimore, MD, USA), the α5 
subunit of the GABA-A receptor is highly expressed in 
the hippo  campus, and agonists for this subunit, such as 
levetri  acetam, can improve cognition in age-impaired 
rats; this drug is now being tested in elderly humans for 
cognition-improving eﬀ  ects.
Instead of targeting a speciﬁ   c pathway disrupted by 
pathological Aβ signaling, Susan Catalano (Cognition 
Th   erapeutics, Inc., Pittsburgh, PA, USA) presented 
eﬀ  orts to block Aβ oligomer binding to neurons. Using a 
membrane traﬃ   ck  ing assay, Dr Catalano found several 
small-molecule compounds that competitively inhibit Aβ 
oligomer-induced perturbations and can rescue synaptic 
defects and cognitive impairments in transgenic AD 
mice. Current studies are underway to test for eﬃ   cacy as 
a chronic, preventative treatment.
Tangle pathology and frontotemporal dementia
Beyond Aβ-associated dysfunction, tau pathology also 
ﬁ  gures prominently in several diseases, including AD and 
FTD. In these diseases, there is a shift in the dynamic 
equilibrium between free and microtubule-associated 
tau, leading to tau aggregation, microtubule destabiliza-
tion, and disrupted cellular transport. Carlo Ballatore 
(University of Pennsylvania School of Medicine, Phila-
delphia, PA, USA) focuses on small-molecule compounds 
that can prevent or reverse tau aggregation. Using in vitro 
tau ﬁ   brillization assays, he identiﬁ  ed  aminothienoy-
ridazine as a highly selective tau ﬁ  brillization inhibitor 
that prevents tau oligomer buildup without disrupting 
normal tau function.
Another approach to ameliorating tau pathology is to 
decrease levels of the tau-4R splice isoform, which aggre-
gates more readily than tau-3R. As discussed by Michael 
Wolfe (Harvard University, Cambridge, MA, USA), this 
splicing process is regulated by a stem-loop structure in 
tau mRNA. To decrease levels of the tau-4R isoform, Dr 
Wolfe screened for compounds that can bind and 
stabilize this stem-loop structure and identiﬁ  ed a cancer 
drug, mitoxantrone, as an eﬀ   ective but nonspeciﬁ  c 
treatment. To increase speciﬁ   city for tau mRNA, Dr 
Wolfe is testing the use of an antisense nucleic acid tag 
conjugated to mitoxantrone to target the compound to 
the regions ﬂ  anking the stem-loop structure.
Hyperphosphorylated tau is a signiﬁ  cant pathological 
feature of several dementias. In AD, elevated homo  cys-
teine levels can inhibit phosphoprotein phosphatase 2A, 
which then leads to a buildup of hyperphosphorylated 
tau. Jeﬀ   ry Stock (Signum Biosciences, Monmouth 
Junction, NJ, USA) has found a compound present in 
coﬀ  ee, SIG1012, which reduces phosphatase 2A inhibi-
tion and tau phos  phory  lation. In vivo tests showed that 
treatment with the compound delays motor defects and 
improves survival in the JNPL3 tauopathy mouse model.
Despite relatively high research investments, Aβ 
immunotherapy does not appear to be eﬀ  ective after the 
onset of signiﬁ  cant cognitive impairments and high plaque 
load. Since tau deposition correlates better with cognitive 
decline, Einar Sigurdsson (New York University Langone 
Medical Center, New York, NY, USA) suggests that tau 
may be a better target for immunotherapy after the 
diagnosis of AD. Using tauopathy mouse models, Dr 
Sigurdsson was able to decrease tau aggregates in the brain 
and improve motor and cognitive function with both 
active and passive immunization targeting phospho-tau.
Another way to clear tau aggregates is via macro  auto-
phagy, which is a cellular process leading to the seques-
tration and degradation of dysfunctional organelles and 
misfolded proteins. Wai Haung Yu (Columbia University, 
New York, NY, USA) has found two compounds – 
rapamycin and trehalose – that stimulate autophagy and 
decrease patho  logical tau aggregates. Trehalose, which 
has good blood–brain barrier penetration, was eﬀ  ective 
as both a therapeutic agent after disease onset as well as a 
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func  tion in the JNPL3 mouse model. Dr Yu’s studies 
point to macroautophagy as a potential drug target for 
enhancing the clearance of protein aggregates in AD as 
well as other neurodegenerative diseases.
Conclusion
At this conference, many exciting new strategies and 
targets for AD drug discovery were presented and will 
hopefully pioneer eﬀ   ective diagnostic and therapeutic 
treatments in the near future. We hope you will join us 
next year for the 12th International Conference on 
Alzheimer’s Drug Discovery, 26–27 September 2011, in 
Jersey City, NJ, USA.
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